Introduction
============

HIV-1 is a well-studied enveloped retrovirus that exploits primary and secondary cellular receptors to gain entry into host cells, which requires fusion interactions of the host receptor and viral ligands. These classical receptors include CD4 and the chemokine receptors CCR5 and CXCR4. Intriguingly, HIV-1 particles have been detected in cells that lack these receptors, suggesting the existence of a non-traditional pathway by which HIV-1 can gain cellular entry using unique molecules that enhance infection.[@b1-ijn-12-4823]--[@b4-ijn-12-4823]

One important feature of HIV-1 is its envelope, which it acquires upon exiting the host cell. The envelope gives HIV-1 a barrier that shields the virus from the immune system due to lipids and proteins derived from the target cell's membrane with major roles in HIV-1's pathogenicity.[@b5-ijn-12-4823] Although the envelope's proteins are more studied than its phospholipids, one major phospholipid of interest is phosphatidylserine (PtdSer),[@b6-ijn-12-4823] whose roles may include functioning as a cofactor for viral fusion with the cell, promoting cell--cell interactions, and acting as a target for specific binding proteins.[@b7-ijn-12-4823]

PtdSer receptors facilitate apoptotic mimicry, a normal cellular mechanism that viruses exploit to gain entry into the cell.[@b8-ijn-12-4823] Because HIV-1 is rich in PtdSer, the virus likely has affinity for these receptors, such as human T cell immunoglobulin and mucin (TIM) protein. Human TIM proteins (TIM-1, TIM-3, and TIM-4) may have very important roles in immunological responses, such as inflammation and oral tolerance,[@b9-ijn-12-4823] and act as a receptor for PtdSer.[@b10-ijn-12-4823] Many enveloped viruses use TIM proteins to augment viral entry,[@b11-ijn-12-4823]--[@b13-ijn-12-4823] including West Nile virus, Ebola virus, and dengue virus, via exposed PtdSer molecules on the surface of the virion.[@b11-ijn-12-4823],[@b14-ijn-12-4823]

We demonstrated in our previous work that TIM-4 in primary mouse neural stem cell (NSC)-derived exosomes participates in the cellular entry of adenovirus, a non-enveloped virus.[@b15-ijn-12-4823] Treatment with anti-TIM-4 antibody significantly blocked exosome-mediated adenovirus entry. Exosomes are 30--200 nm nanostructures secreted from donor cells into various body fluids[@b16-ijn-12-4823],[@b17-ijn-12-4823] and internalized by recipient cells. Exosomes are routinely released at the plasma membranes of different types of cells, facilitate intercellular communication,[@b17-ijn-12-4823],[@b18-ijn-12-4823] and mediate adaptive immune responses to pathogens and tumors by transferring soluble factors, proteins, mRNA, and microRNAs to recipient cells.[@b17-ijn-12-4823],[@b19-ijn-12-4823] Feng et al[@b20-ijn-12-4823] determined that TIM-4 is involved in the uptake of exosomes and that they enter cells via phagocytosis.

Here, we demonstrate that HIV-1 entry into human immune cells is enhanced by exosome-mediated trafficking and mediated partially through TIM-4.

Methods
=======

Cell culture
------------

Human CD4^+^ lymphoblastoid T cell line (line A3R5.7) was a gift from the UAB CFAR Virology core. These cells were commercially received from the NIH AIDS Research and Reference Reagent Program and subsequently genetically modified. A3R5.7 cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated, exosome-free fetal bovine serum, 2 mM L-glutamine, penicillin (100 U/mL), streptomycin (100 μg/mL) (Thermo Fisher Scientific, Waltham, MA, USA), and 1 mg/mL geneticin (G418; Thermo Fisher Scientific). Human monocytic cells (line THP2574) were maintained in similar medium but without geneticin.[@b21-ijn-12-4823],[@b22-ijn-12-4823] All other cell lines were purchased from American Type Culture Collection.

Exosome purification
--------------------

### Isolation of NSC-derived exosomes

Mouse cortical NSCs were cultured in serum-free culture medium for exosome extraction. In brief, cells were centrifuged at 5,000 rpm for 10 min at 4°C using a Sorvall RT600 centrifuge with a swinging bucket rotor (Thermo Fisher Scientific). The supernatant was clarified by filtration through a 0.22 μm filter and centrifuged at 32,000 rpm for 70 min at 4°C using an SW41T1 swinging rotor in a Beckman Coulter (Brea, CA, USA) Optima L-70K ultracentrifuge for exosome collection.[@b15-ijn-12-4823],[@b19-ijn-12-4823] Exosomes were resuspended in 120--450 μL sterile phosphate-buffered saline (PBS) and then quantified by Bradford protein quantitation method.

### Isolation of human lung cell carcinoma-derived exosomes

Cell line A549 was grown in RPMI 1640 complete medium containing exosome-free fetal bovine serum to \~80% con-fluency. The cell culture medium was centrifuged at 5,000 rpm for 10 min at 4°C and clarified by filtration through a 0.22 μm filter. The filtrate was then centrifuged at 32,000 rpm for 70 min to collect exosomes,[@b15-ijn-12-4823],[@b19-ijn-12-4823] which were resuspended in 120--450 μL sterile PBS.

### Isolation of breast milk-derived exosomes

Breast milk samples were collected from samples prior to being discarded from healthy human donors and centrifuged twice at 3,500 rpm for 10 min at 4°C. The fat layer was aspirated and the supernatant transferred to a new tube. A third spin was performed at 5,000 rpm for 30 min at 4°C, after which the remaining fat was aspirated and the supernatant transferred to a new tube. Breast milk was then filtered with a 0.22 μm filter, transfered into ultracentrifuge tube and then the tube volume was adjusted with PBS prior to an ultracentrifugation spin at 32,000 rpm for 70 min at 4°C. The pellet was collected and resuspended in 120--450 μL sterile PBS.

### Isolation of human plasma-derived exosomes

Plasma was collected from whole blood of human donors into tubes containing ethylenediaminetetraacetic acid (EDTA) and processed as described by Konadu et al[@b23-ijn-12-4823] with some modifications. Whole-blood samples were centrifuged at 3,500 rpm for 10 min at 4°C. If the samples contained a high lipid content after the low-speed centrifugation (evidenced by color), they were incubated for 2 h at 4°C, and the precipitated fat was removed by centrifugation at 5,000 rpm for 10 min at 4°C. The supernatants were then filtered through a 0.22 μm filter and ultracentrifuged for 30 min at 32,000 rpm at 4°C. The pellet was collected by centrifuging the samples at 27,000 rpm for 2 h at 4°C. The resulting pellet was resuspended in 1 mL PBS, loaded on to OptiPrep velocity gradients, and subjected to flotation centrifugation at 27,000 rpm for 2 h. Fractions with peak exosome content (fractions 2 and 3) were pooled, diluted with PBS, and ultra-centrifuged for 2 h at 32,000 rpm. The exosome pellet was resuspended in 120 μL PBS.

SDS-PAGE and Western blot analyses of exosome-associated proteins
-----------------------------------------------------------------

To analyze proteins associated with exosomes, exosomes were mixed with loading buffer (1:1), boiled, and resolved on a 4%--12% Bis--Tris gel, followed by transfer and blocking on a polyvinylidene difluoride membrane. Blotting was performed with four different primary antibodies: anti-clathrin monoclonal antibodies (1:1,000; BD Biosciences, San Jose, CA, USA), anti-CD9 (1:1,000; System Biosciences, Inc., Palo Alto, CA, USA), anti-CD63 (1:1,000; System Biosciences, Inc.), and anti-TIM-4 (1:1,000; Sino Biological, Inc., Beijing, China) antibodies. Then incubation with secondary antibodies was performed using either horseradish peroxidase (HRP)-conjugated goat anti-mouse (1:2,000; Dako Denmark A/S, Glostrup, Denmark) or anti-rabbit (1:20,000; System Biosciences, Inc.) antibodies. Proteins were detected using an enhanced chemiluminescence kit (ELC Western Blotting Substrate Pierce/Thermo Fisher Scientific) and a Bio-Rad ChemiDoc XRS system (Bio-Rad Laboratories, Hercules, CA, USA).

HIV-1 infection of human cell lines
-----------------------------------

HIV-1 experiments were conducted using an infectious molecular clone (NL-LucR.T2A-YU2.ecto \[YU-2\]) engineered to express *Renilla* luciferase (LucR) and ENV from the YU-2 virus strain, which was derived from the postmortem brain of a patient with HIV-associated neurocognitive disorder (HAND).

A3R5.7 cells were seeded on 96-well plates at a density of 1×10^5^ cells/well with the addition of 5 μg/mL diethylaminoethyl-dextran.[@b24-ijn-12-4823] Exosomes derived from NSC, A549, breast milk, and plasma were incubated, respectively, with YU-2 at a multiplicity of infection (MOI) of 0.002 for 1 h at 37°C in 5% CO~2~,[@b25-ijn-12-4823] and then HIV-1/exosome mixture was co-incubated with the cells for 72 h at 37°C in 5% CO~2~. LucR activity was determined using the *Renilla* Luciferase Assay System (Promega Corporation, Fitchburg, WI, USA). Relative luminescence units (RLUs) were measured in triplicate on a Victor X light luminescence counter (PerkinElmer Inc, Waltham, MA, USA) with an exposure time of 0.1 s/well.

THP2574 cells (1×10^4^ cells/well) were classically differentiated into macrophages with 1 ng/mL phorbol 12-myristate 13-acetate for 96 h. Clone YU-2 with an MOI of 0.18 was incubated with exosomes for 1 h at 37°C in 5% CO~2~. The HIV-1/exosome mixture was co-incubated with the cells for 72 h at 37°C in 5% CO~2~, and LucR activity was measured in triplicate as described earlier.

Amounts of exosomes and viral MOIs used for each cell line were determined experimentally. The following quantities of exosomes, which would saturate all HIV-1 virions, were used for viral entry experiments: 0.1 μg NSC-derived exosomes, 0.035 μg breast milk-derived exosomes, 0.05 μg plasma cell-derived exosomes, and 0.1 μg A549-derived exosomes.

Blocking of HIV-1 infection
---------------------------

A protocol similar to HIV-1 infection was performed but with addition of 0.2 μg/well anti-mouse TIM-4 or anti-human TIM-4 (Sino Biological, Inc.) to the YU-2/exosome/cell incubation or with YU-2 only as a control.

Determining exosome size and concentration
------------------------------------------

We used nanoparticle tracking analysis (NTA) using the Nano-Sight LM10 (Malvern Instruments, Inc., Malvern, UK) and NTA v2.0 software to characterize breast milk- and plasma-derived exosomes. All data were collected using five frames and in triplicate. Samples were diluted 1:1,000 prior to tracking, which led to particle sizes of 10^−7^--10^−9^ m. Mean values were recorded and analyzed for each given reading frame.

Human study participants
------------------------

The study was approved by the Institutional Review Board (IRB) for the Protection of Human Subjects in Research at the University of Alabama at Birmingham (UAB) in accordance with approved guidelines and protocol. Breast milk was collected from samples prior to being discarded at the UAB Regional Newborn Intensive Care Unit with expedited IRB approval. Blood donors provided written informed consent prior to donation.

Statistical analysis
--------------------

One-way analysis of variance with a post hoc Tukey's test was performed on obtained data points, and results are presented as mean ± standard error of the mean (SEM). Statistical significance was defined as *P*≤0.05.

Results
=======

Isolation and characterization of exosomes
------------------------------------------

Exosomes were isolated and characterized for exosomal markers, such as CD9 and CD63, as described in our previous study.[@b15-ijn-12-4823] For these studies, we isolated exosomes from two cell lines, NSC and human lung carcinoma (A549). We also isolated exosomes from human breast milk and human plasma using published methods.[@b15-ijn-12-4823],[@b23-ijn-12-4823] To confirm successful exosome isolation, we performed a series of SDS-PAGE and Western blot analyses to examine expression of well-known exosomal proteins ([Figure 1A and B](#f1-ijn-12-4823){ref-type="fig"}). Specifically, breast milk exosomes incubated with anti-clathrin and −CD9 antibodies yielded protein bands at 180 kDa and 28 kDa, respectively ([Figure 1A1 and A2](#f1-ijn-12-4823){ref-type="fig"}). Similarly, analysis of human plasma exosomes incubated with anti-CD9 and −CD63 antibodies confirmed their presence as well ([Figure 1B1 and B2](#f1-ijn-12-4823){ref-type="fig"}). Moreover, Western blotting detected TIM-4 associated with human plasma exosomes ([Figure 1C](#f1-ijn-12-4823){ref-type="fig"}), which we had previously found on NSC-derived exosomes.[@b15-ijn-12-4823]

We used NTA to validate our exosome population from human biological samples ([Figure 1D](#f1-ijn-12-4823){ref-type="fig"} and [1E](#f1-ijn-12-4823){ref-type="fig"}). Human plasma exosomes ([Figure 1D](#f1-ijn-12-4823){ref-type="fig"}) have a mean diameter size of 180 nm ±64.1 nm and mean concentration of 1.68×10^9^±4.00×10^7^ particles/mL. Human breast milk-derived exosomes ([Figure 1E](#f1-ijn-12-4823){ref-type="fig"}) have a mean size of 116.2 nm ±56.2 nm and mean concentration of 3.42×10^6^±3.91×10^5^ particles/mL.

NSC- and A549 cell-derived exosomes augment HIV-1 entry into human T lymphoblastoid and differentiated macrophage cell lines
----------------------------------------------------------------------------------------------------------------------------

We previously showed that mouse NSC-derived exosomes mediate adenoviral entry independent of the Coxsackie virus and adenovirus receptor[@b15-ijn-12-4823] and that this entry is blocked by anti-TIM-4 antibody. As proof of principle, we used mouse NSC-derived exosomes in this study to determine if they could facilitate cellular entry of an HIV-1 variant derived from a patient diagnosed with HAND.

The NSC-derived exosomes represent an orthotropic mechanism for brain-specific exosome-mediated HIV-1 entry in vitro, so we investigated if mouse NSC-derived exosomes significantly enhance HIV-1 entry and induce viral gene expression as indicated by LucR activity. To determine the impact of exogenous exosomes on HIV-1 entry and subsequent gene expression, we performed a series of viral infection experiments using exosomes only (as mock infection), YU-2 only, and exosomes with YU-2 only or with YU-2 and added anti-TIM-4 antibody. TIM-4-blocking experiments were based on previously published experimental dose titrations.[@b15-ijn-12-4823] The above mentioned combinations were administered to either the T lymphoblastoid cell line A3R5.7 or the macrophage-like cell line THP2574.

YU-2 alone infected A3R5.7 cells and induced viral gene expression, which was measured at \~200,000 RLU. Co-incubation of YU-2 with 0.1 μg NSC-derived exosomes increased the number of RLU significantly (*P*≤0.0001) compared to YU-2 only. This increased exosome-mediated HIV-1 gene expression was reversed when TIM-4 blocking was performed via anti-TIM-4 antibodies (*P*≤0.0001) ([Figure 2A](#f2-ijn-12-4823){ref-type="fig"}).

In THP2574 macrophages, YU-2 alone infected the cells and yielded \~600,000 RLU ([Figure 2B](#f2-ijn-12-4823){ref-type="fig"}). Co-incubation of YU-2 with NSC-derived exosomes significantly increased the number of RLU (*P*=0.0221) compared to YU-2 only. Administration of a combination of NSC-derived exosomes, YU-2, and anti-TIM-4 led to a significant decrease in RLU compared to the administration of YU-2 only (*P*=0.001) and NSC-derived exosomes with YU-2 (*P*≤0.0001). The addition of anti-TIM-4 antibody significantly diminished viral gene expression, further illustrating the specificity of TIM-4/exosome interactions in multiple human cell types.

HIV-1-infected patients experience increased incidence of cancer, especially non-AIDS-defining cancers (NADCs), such as lung cancer. To investigate if cancer cell-derived exosomes can fuel HIV-1 pathogenesis in A3R5.7 and THP2574 cells, we used human lung carcinoma cells (A549)-derived exosomes. [Figure 2C](#f2-ijn-12-4823){ref-type="fig"} shows that co-incubation of YU-2 with 0.1 μg A549 cell-derived exosomes significantly increased HIV-1 entry in A3R5.7 cells (*P*=0.0004) compared to the YU-2-only control. Anti-TIM-4 antibodies significantly limited exosome-mediated HIV-1 entry into A3R5.7 (*P*≤0.0000) and THP2574 cells (*P*≤0.0001) and subsequent viral gene expression. We also validated the ability of human A549-derived exosomes to significantly enhance HIV-1 entry into macrophages (*P*=0.0001; [Figure 2D](#f2-ijn-12-4823){ref-type="fig"}).

Breast milk- and plasma-derived exosomes augment HIV-1 entry into human target cell lines
-----------------------------------------------------------------------------------------

A noteworthy proportion of mother-to-child transmission (MTCT) cases of HIV-1 occurs during breastfeeding in situations where replacement feeding is unsafe or impractical.[@b26-ijn-12-4823] Breast milk-derived exosomes enhanced YU-2 entry into A3R5.7 cells, but not significantly, compared to YU-2 alone ([Figure 3A](#f3-ijn-12-4823){ref-type="fig"}). However, anti-TIM-4 antibodies notably blocked YU-2 entry (*P*≤0.0001). In contrast, we observed that breast milk-derived exosomes significantly enhanced YU-2 entry into THP2574 macrophages (*P*=0.008) compared to YU-2 alone, while addition of anti-TIM-4 antibody decreased YU-2 entry into the cells ([Figure 3B](#f3-ijn-12-4823){ref-type="fig"}).

Because HIV-1 transmission also frequently occurs through blood exchange, we also evaluated the ability of plasma-derived exosomes to promote HIV-1 cellular entry. We validated the ability of the plasma exosomes to enhance YU-2 entry into human T cell line A3R5.7. Co-incubation of YU-2 with plasma-derived exosomes significantly enhanced YU-2 entry into AR35.7 cells (*P*=0.001) compared to YU-2 only ([Figure 3C](#f3-ijn-12-4823){ref-type="fig"}), which was subsequently blocked by anti-TIM-4 antibodies. [Figure 3D](#f3-ijn-12-4823){ref-type="fig"} shows that co-incubation of HIV-1 with plasma exosomes also increased HIV-1 entry into THP2574 cells (*P*≤0.0001), and its entry was again significantly blocked by anti-TIM-4 antibodies (*P*≤0.0001).

Because the HIV-1 envelope contains abundant PtdSer, we investigated the possibility of HIV-1 direct cellular entry via binding to cellular TIM-4. In a subset of HIV-1 entry experiments ([Figure S1](#SD1-ijn-12-4823){ref-type="supplementary-material"}), we evaluated an additional control treatment of anti-TIM-4 antibodies and YU-2 only (no exosomes) to THP2574 cells. We observed similar viral gene expression levels between the YU-2-only and the TIM-4-blocking groups, suggesting that HIV-1 cannot directly enter human T cells via binding to cellular TIM-4.

Discussion
==========

Growing evidence details the role of exosomes in viral pathogenesis. Exosomes are present in many body fluids, such as amniotic fluid, ascites fluid, breast milk, bronchoalveolar lavage, cerebrospinal fluid, plasma, saliva, semen, and urine,[@b27-ijn-12-4823]--[@b35-ijn-12-4823] and we investigated HIV-1 interactions with exosomes from various sources. Retroviruses may have important similarities to exosomes and can exploit the exosome biogenesis pathway, which aids in viral dissemination. This mechanism, described in the Trojan exosome hypothesis, involves envelope- and receptor-independent viral entry.[@b36-ijn-12-4823],[@b37-ijn-12-4823]

Exosomes inhibit or promote HIV-1 infections, depending on their cellular context. Blood-derived exosomes promote HIV-1 infection via CCR5/CXCR4, Gag, viral mRNA/miRNA, TAR RNA, CD45/CD86, and tumor necrosis factor-α (TNF-α);[@b38-ijn-12-4823]--[@b44-ijn-12-4823] HIV-1 infection can be inhibited by the same exosomes via APOBEC3G, CD4, interferon (IFN)-α, IFN-β, and various interleukins.[@b45-ijn-12-4823]--[@b50-ijn-12-4823] Exosomes derived from breast milk or semen can also inhibit HIV-1 infection via IgA, IgG, mucin 1, and oligosaccharides,[@b51-ijn-12-4823]--[@b53-ijn-12-4823] although semen-derived exosomes only inhibit HIV-1 entry specifically via mucin 6.[@b54-ijn-12-4823] The effects of exosomes from other body fluids, such as urine, saliva, bronchoalveolar lavage, and cerebro-spinal fluid, on HIV-1 entry are currently unexplored.

We characterized purified exosomes by SDS-PAGE, Western blotting, and NTA. In addition to confirming the presence of exosomal markers, we verified the presence of TIM-4 on exosomes derived from primary mouse NSCs and human plasma. Here, we evaluated a genetically modified HIV-1 variant of YU-2, a strain isolated from patients with HIV-associated dementia, thus representing an HIV-1 strain relevant for assessing central nervous system (CNS)-related investigations.[@b25-ijn-12-4823] The current paradigm of HIV-1 infection in the CNS involves monocyte- and macrophage-mediated entry via the CD4/CCR5 receptor. However, CD4^−^ brain cells can also be infected with HIV-1 and can act as active HIV-1 reservoirs. One proposed alternative infection pathway involves Trojan exosomes, which may cross the blood--brain barrier or be released from cells within the CNS. Our first set of HIV-1 entry experiments involved NSC-derived exosomes and demonstrated that mouse NSC-derived exosomes enhanced YU-2 viral entry into human target cells.

This study expands on our previous finding that mouse NSC-derived exosomes promoted entry of adenovirus, a non-enveloped virus, into an adenovirus-deficient cell line.[@b15-ijn-12-4823] We also detected TIM-4 on the surface of the exosomes and found that the protein interacts with adenovirus type 5, leading us to hypothesize that exosomal TIM-4 may also play a role in HIV-1 trafficking.

Our proposed mechanism of HIV-1 entry involves interactions between PtdSer moieties on the virus' envelope and target cell receptors. This mechanism is supported by abundant PtdSer on the HIV-1 envelope, making them likely ligands of phospholipid-binding proteins, such as TIMs.[@b6-ijn-12-4823] Moreover, these proteins have been observed in exosomes and can bind to HIV-1. Finally, we determined that when TIM-4 is blocked by anti-TIM-4 antibodies, interactions between HIV-1 and exosomes decrease, leading to reduced HIV-1 entry into human T lymphoblastoid and macrophage cell lines.

We also investigated the ability of lung carcinoma cell-derived exosomes to enhance YU-2 entry into both human cell lines. Cancer cell-derived exosomes are involved in cancer metastasis,[@b55-ijn-12-4823] and pulmonary malignancies, including NADCs, which are a major cause of morbidity and mortality in HIV-infected individuals.[@b56-ijn-12-4823] HIV-associated factors appear to increase the risk of lung cancer and may adversely impact cancer treatment and outcomes in NADC patients. We speculate that cancer cell-derived exosomes, in addition to participating in cancer progression, may facilitate HIV-1 pathogenesis and dissemination to unlikely organ types.

MTCT accounts for \~260,000 new HIV-1 infections annually, with the majority of cases in sub-Saharan Africa, and one-third to one-half of these infections occur postpartum.[@b57-ijn-12-4823]--[@b59-ijn-12-4823] Breast milk-mediated MTCT of HIV-1 remains an enigma, so identifying the ability of breast milk components that promote or inhibit HIV-1 MTCT could help limit the occurrence of postpartum HIV-1 transmission. Human breast milk contains many antibacterial and antiviral compounds, and breast milk-derived exosomes have been shown to inhibit HIV-1 infection. In this study, we evaluated the impact of breast milk-derived exosomes on HIV-1 entry and found that their co-incubation with YU-2 did enhance viral entry into the T cell line, although the enhancement was not statistically significant. However, TIM-4 blocking dramatically reduced YU-2 entry, indicating that multiple factors may impact exosome, HIV-1, and T cell interactions and necessitating further investigation. Alternatively, breast milk-derived exosomes significantly promoted HIV-1 entry into macrophages, and, like in T cells, viral entry was inhibited using anti-TIM-4 antibodies. We also evaluated the effect of plasma-derived exosomes on YU-2 entry into the two cell lines. These exosomes increased YU-2 entry more than any other exosome type, but viral entry was again blocked by addition of anti-TIM-4 antibodies. Thus, our findings suggest a direct relationship between HIV-1 entry and exosomes.

Exosome and anti-TIM-4 antibody concentrations were calculated for saturation of YU-2 viral particles in our infection experiments. Therefore, the incomplete inhibition of YU-2 entry into A3R5.7 cells co-incubated with NSC-derived exosomes and anti-TIM-4 antibodies indicates that other TIMs or related proteins mediate exosome and viral entry in different cellular contexts. However, with the exosomes we evaluated, TIM-4 acts as the dominant mediator.

Our findings implicate exosomes as enhancers of HIV-1 viral entry into multiple human cell types. For future study, stringent profiling for identifying specific exosome-associated proteins (eg, TIM-1 or TIM-3) may explain why various types of exosomes differentially influence YU-2 entry into target cells and are affected by TIM-4 blocking in different ways. Although we found that exosomes generally increase HIV-1 entry into both T cells and macrophages, additional analyses with exosomes from HIV-1-infected patient samples will also improve our understanding of virus and exosome interactions and HIV-1 pathogenesis.

Supplementary material
======================

###### 

Plasma-derived exosomes augment HIV-1 entry in a monocyte/macrophage cell line.

**Notes:** The THP2574-derived macrophages were used for this entry experiments. YU-2 was used at an MOI of 0.18. Virus entry was evaluated in the absence or presence of plasma-derived exosomes (0.05 μg). Virus entry was evaluated in the presence or absence of exosomes, exosomes and TIM-4 antibody, and TIM-4 only, respectively. Cells only, exosomes only, YU-2 only, YU-2 + exosomes, YU-2 + exosomes + TIM-4 antibody, and YU-2 + TIM-4 antibody were analyzed by luciferase expression at 72 h post-infection. Data represent 12 independent experiments. Experimental significance was determined by one-way ANOVA \*\*\*\**P*\<0.0001. YU-2, (NL-LucR.T2A-YU2.ecto) engineered to express *Renilla* luciferase (LucR) and ENV from the YU-2 virus strain.

**Abbreviations:** MOI, multiplicity of infection; TIM, T cell immunoglobulin and mucin; ANOVA, analysis of variance; RLU, relative luminescence unit; exo, exosomes.
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![Western blot and NTA validation of exosomal samples.\
**Notes:** Western blots of (**A**) breast milk exosomes (60 μg/lane) \[(A1) clathrin and (A2) CD9\] and (**B**, **C**) plasma exosomes (25 μg/lane) \[(B1) CD9, (B2) CD63\], (**C**) TIM-4. Arrows indicate proteins of interest. (**D**, **E**) NTA-generated size and concentration plots for (**D**) human plasma- and (**E**) human breast milk-derived exosomes.\
**Abbreviations:** NTA, nanoparticle tracking analysis; TIM, T cell immunoglobulin and mucin.](ijn-12-4823Fig1){#f1-ijn-12-4823}

![NSC- and A549-derived exosomes significantly enhance HIV-1 entry into human immune cell lines.\
**Notes:** (**A**, **C**) YU-2 virus entry into A3R5.7 cells was evaluated in the presence or absence of (**A**) NSC-derived exosomes (0.1 μg) or (**C**) A549-dervied exosomes (0.1 μg). (**B**, **D**) The differentiated THP2574 cell line was used for entry experiments with YU-2 in the presence or absence of (**B**) NSC-derived exosomes (0.1 μg) or (**D**) A549-derived exosomes (0.1 μg). Virus entry was also evaluated in the presence of exosomes and anti-TIM-4 antibody. Viral gene expression in all control and treatment groups was assessed by *Renilla* luciferase activity at 72 h post-infection. Data represent 12 independent experiments. Significant differences between treatment groups were determined by one-way ANOVA \**P*\<0.05, \*\*\**P*\<0.001, \*\*\*\**P*\<0.0001. YU-2, (NL-LucR.T2A-YU2.ecto) engineered to express *Renilla* luciferase (LucR) and ENV from the YU-2 virus strain.\
**Abbreviations:** NSC, neural stem cell; TIM, T cell immunoglobulin and mucin; ANOVA, analysis of variance; RLU, relative luminescence unit, exo, exosomes.](ijn-12-4823Fig2){#f2-ijn-12-4823}

![Breast milk- and plasma-derived exosomes enhance HIV-1 entry into human immune cell lines.\
**Notes:** (**A**, **C**) YU-2 virus entry into A3R5.7 cells was evaluated in the presence or absence of (**A**) breast milk-derived exosomes (0.035 μg) or (**C**) plasma-derived exosomes (0.05 μg). Virus entry was evaluated in the presence of exosomes and anti-TIM-4 antibodies. (**B**, **D**) The differentiated THP2574 cell line was used for entry experiments with YU-2 in the presence or absence of (**B**) breast milk-derived exosomes (0.035 μg) or (**D**) plasma-derived exosomes (0.05 μg). Virus entry was also evaluated in the presence of exosomes and anti-TIM-4 antibody. Viral gene expression in all control and treatment groups was assessed by *Renilla* luciferase activity at 72 h post-infection. Data represent 12 independent experiments. Significant differences between treatment groups were determined by one-way ANOVA. \*\**P*\<0.01, \*\*\*\**P*\<0.0001. YU-2, (NL-LucR.T2A-YU2. ecto) engineered to express *Renilla* luciferase (LucR) and ENV from the YU-2 virus strain.\
**Abbreviations:** TIM, T cell immunoglobulin and mucin; ANOVA, analysis of variance; RLU, relative luminescence unit; BM, breast milk; exo, exosomes.](ijn-12-4823Fig3){#f3-ijn-12-4823}
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